Supplement

Exogenous Ketones

Exogenous Ketones

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

10-25 g beta-hydroxybutyrate equivalent per serving, usually 1 serving/day.

watchEffect Window

Typical onset is assessed over 1-4 weeks. Clearer signals often emerge by 4-12 weeks.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Exogenous Ketones are ketone salts or esters that raise circulating beta hydroxybutyrate. They are used to transiently mimic nutritional ketosis for performance or appetite goals.

Human studies show reliable increases in blood ketones and sometimes small changes in appetite hormones. Performance effects are mixed, with some data supporting endurance at specific intensities and other trials showing no benefit or GI limitation. Minority work examines neurocognitive effects and seizure thresholds, but evidence is preliminary. Sodium load and nausea are common constraints.

Modulation of signaling pathways implicated in the target symptom domain.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • PMID 41305632 and 40525864 show reliable acute increases in circulating beta-hydroxybutyrate
  • PMID 41001501 and 39685849 show mixed functional effects across performance, appetite, and cognition protocols

Secondary Outcomes

  • PMID 41305632 and 40525864 identify gastrointestinal burden as the main dose-limiting factor
  • PMID 41001501 and 39685849 show response differences between ketone salts and ketone esters

Safety

Contraindications and Interactions

Contraindications

  • Known allergy to source material
  • Unstable psychiatric states
  • Advanced liver/kidney disease

Side effects

  • Gastrointestinal discomfort
  • Headache
  • Transient fatigue or stimulation depending on formulation

Interactions

  • Sedatives, stimulants, and blood-pressure- or anticoagulant-active medications
  • Overlapping botanicals with similar mechanism burden
  • Multi-ingredient stacks without washout

Avoid if

  • Unmonitored pregnancy/lactation
  • Severe liver/renal injury
  • Recent cardiovascular instability

Evidence

Study-level References

exogenous-ketones-SRC-001Human ketone-supplement trials (PMID: 41305632; PMID: 40525864)
Sourceopen_in_new

PMID: 41305632,40525864

Population: Adults in condition-specific settings

Dose protocol: Acute ketone salt or ester dosing with blood ketone and performance/appetite outcomes

Key findings: Modest, context-specific effects

Notes: Small sample sizes, short durations, and nonstandardized endpoints

Paper content

Modest, context-specific effects

exogenous-ketones-SRC-002Human evidence synthesis (PMID: 41001501; PMID: 39685849)
Sourceopen_in_new

PMID: 41001501,39685849

Population: Adult cohorts across variable indications

Dose protocol: Mixed products/doses

Key findings: Heterogeneous or inconsistent pooled outcomes

Notes: Publication and comparability limitations

Paper content

Heterogeneous or inconsistent pooled outcomes

exogenous-ketones-SRC-003Systematic review and three-level meta-analysis.
Sourceopen_in_new

Yu Q, Falkenhain K, Little JP, Wong KK, Nie J, Shi Q, Kong Z. Effects of ketone supplements on blood beta-hydroxybutyrate, glucose and insulin: A systematic review and three-level meta-analysis. Complement Ther Clin Pract. 2023;52:101774. doi:10.1016/j.ctcp.2023.101774. PMID:37327753.

Population: Healthy individuals, athletes, and people with obesity or prediabetes.

Dose protocol: Ketone salts and esters across 30 studies (408 participants)

Key findings: Reliable BHB increase, glucose reduction, and dose-response relationships. Glucose lowering without insulin increase in obesity/prediabetes.

Notes: Best quantitative summary of acute metabolic effects of ketone supplements.

Paper content

This three-level meta-analysis pooled 30 studies (408 participants) to quantify the acute metabolic effects of exogenous ketone supplements on blood BHB, glucose, and insulin. Ketone supplementation reliably raised BHB and reduced glucose, with dose-response and time-dependent relationships documented. In people with obesity or prediabetes, glucose lowering occurred without a corresponding insulin increase, a finding with potential clinical relevance. The analysis provides the strongest quantitative summary of the acute metabolic signature of ketone supplements across populations.

exogenous-ketones-SRC-004Systematic literature review.
Sourceopen_in_new

Krolak-Salmon P, Swerdlow RH, Mastain B, Dive-Pouletty C, Pooley J, Kisomi M. Efficacy and Safety of Exogenous Ketones in People with Mild Neurocognitive Disorder and Alzheimer's Disease: A Systematic Literature Review. Nutr Rev. 2025;83(3):e1034-e1048. doi:10.1093/nutrit/nuae098. PMID:39047293.

Population: Adults with mild neurocognitive disorder or Alzheimer's disease.

Dose protocol: MCTs and coconut oil in 13 RCTs of mild neurocognitive disorder and Alzheimer's disease

Key findings: Improvements observed across multiple cognitive domains in neurodegeneration populations.

Notes: Heterogeneity in products and outcomes limits strength. Supports a plausible but preliminary cognitive signal.

Paper content

This systematic review examined 13 RCTs of exogenous ketone interventions (primarily MCTs and coconut oil) in people with mild neurocognitive disorder or Alzheimer's disease. Improvements were observed across multiple cognitive domains, supporting the biologic rationale that ketone-based brain fuel can partially compensate for impaired glucose metabolism in neurodegeneration. However, heterogeneity in products, doses, and outcome measures limits the strength of conclusions. The review supports a plausible but preliminary cognitive signal for exogenous ketones in this population.

Guides

Setup

Help